MARK2 and neoplasm: STK11 mutations in NSCLC may be associated with worse outcomes with ICIs since the inactivation of this serine threonine kinase involved in various cellular functions is associated with a low T lymphocytes tumor infiltration and a “cold” tumor microenvironment (21, 22).